re:VASO
I've also followed Vaso for a few years. I can't speak to management's shady practices, but do know that this new PR report is not a repeat of previous ones. VASO had been FDA approved for end-line treatment of angina, meaning those patients who were not candidates for surgical intervention. The new study shows EECP benefits surgical candidates also, which opens the field to a huge number of patients.
I don't believe VASO has any competitor for it's noninvasive treatment and medications have gone as far as they can. Also true-this field is dominated by the cardiac cath lab and it's quick fix, and the surgeon's knife with bypass. VASO's product may take years to muscle in on this lucrative field.
Medicare reimbursement rate was tied to the physician payment.
VASO will get big recognition if and when it gets approved for congestive heart failure. (I believe it will, by the nature of the product.)
Market Data 
Markets 
AI
